Multimodal Diffusion MRI Synergized with VI-RADS for Precision Grading of Bladder Urothelial Carcinoma: A Prospective Diagnostic Model Validation
Academic Radiology · 2025
DOI: 10.1016/j.acra.2025.05.014 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Academic Radiology, 2025. Verfasst von Xiaoxian Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China (X.Z., L.W., S.Z., X…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Diffusion Magnetic Resonance Imaging, Multimodal Imaging, Carcinoma, Transitional Cell. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
RATIONALE AND OBJECTIVES: To evaluate the diagnostic performance of diffusion tensor imaging (DTI), diffusion kurtosis imaging (DKI), mean apparent propagator (MAP), neurite orientation dispersion and density imaging (NODDI), and the Vesical Imaging-Reporting and Data System (VI-RADS) in discriminating the pathological grade of bladder urothelial carcinoma (UCB). MATERIALS AND METHODS: This prospective study enrolled patients with pathologically confirmed UCB between May 2023 and December 2023. Preoperative MRI protocols included spin-echo echo-planner imaging (SE-EPI) and conventional DWI. Quantitative parameters from SE-EPI (DTI, DKI, MAP, NODDI) and apparent diffusion coefficient (ADC) values were measured. Group comparisons between low-grade and high-grade UCB were performed using t-tests or Mann-Whitney U tests. Receiver operating characteristic (ROC) analysis and DeLong's test were used to evaluate diagnostic performance. RESULTS: A total of 50 patients with UCB (low-grade/ high-grade = 16/34) were included. VI-RADS score and mean kurtosis (MK) derived from DKI emerged as independent predictors for differentiating low-grade and high-grade UCB (area under the curve (AUC): 0.692 and 0.865, respectively). The combination of VI-RADS and DKI-MK achieved superior diagnostic performance (AUC: 0.915, sensitivity: 0.941) compared to VI-RADS alone (AUC: 0.692, sensitivity: 0.471; p < 0.001) or ADC alone (AUC: 0.787, sensitivity: 0.813; p < 0.05). CONCLUSION: Integrating VI-RADS with DKI-MK significantly enhances preoperative assessment of UCB pathological grading, demonstrating higher accuracy and sensitivity than VI-RADS or ADC alone. This approach improves diagnostic objectivity by combining qualitative imaging criteria with quantitative diffusion metrics, offering potential clinical utility for treatment stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China (X.Z., L.W., S.Z., X.C., C.X.).
- MR Research Collaboration, Siemens Healthineers, Shanghai 201318, China (S.W., M.W.).
- Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China (X.Z., L.W., S.Z., X.C., C.X.). Electronic address: xcm-1977@163.com.
Zitieren
APA
Zhang, X., Wang, S., Wang, M., Wang, L., Zhang, S., Chen, X., & Xu, C. (2025). Multimodal Diffusion MRI Synergized with VI-RADS for Precision Grading of Bladder Urothelial Carcinoma: A Prospective Diagnostic Model Validation. Academic Radiology. https://doi.org/10.1016/j.acra.2025.05.014
Vancouver
Zhang X, Wang S, Wang M, Wang L, Zhang S, Chen X, et al. Multimodal Diffusion MRI Synergized with VI-RADS for Precision Grading of Bladder Urothelial Carcinoma: A Prospective Diagnostic Model Validation. Academic Radiology. 2025. doi:10.1016/j.acra.2025.05.014
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaoxian and Wang, Shaoyu and Wang, Mengzhu and Wang, Lifeng and Zhang, Shouning and Chen, Xuejun and Xu, Chunmiao},
title = {Multimodal Diffusion MRI Synergized with VI-RADS for Precision Grading of Bladder Urothelial Carcinoma: A Prospective Diagnostic Model Validation},
journal = {Academic Radiology},
year = {2025},
doi = {10.1016/j.acra.2025.05.014}
}
EUVIMED